Back to Top

Annemieke DeMaggio's blog

Accelerated FDA approval for pralsetinib in RET-fusion positive NSCLC

Approval based on the NSCLC cohorts included in the ARROW phase 1/2 study. Data from thyroid cancer cohorts has been filed; PDUFA in February 2021

ESMO 2020 Preview, part 2: new and/or notable

As expected, the majority of ESMO orals will be IO related. As for small molecules, oral presentations include the usual line up of targets, but also some things new or noteworthy.


Subscribe to RSS - Annemieke DeMaggio's blog